The Pharmaceutical Market: Singapore

Date: January 31, 2013
Pages: 112
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P778A667946EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Singapore
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SINGAPORE

Singapore will be of moderate attractiveness to investors given its small pharmaceutical market size, despite the growing demands for more pharmaceuticals and healthcare from its increasingly ageing population. However, the city-state will continue to attract companies looking to set up regional offices, manufacturing hubs or research and development facilities in the country given its strong regulatory framework and relatively stable political and economic environment.

Headline Expenditure Projections

Pharmaceuticals: SGD901mn (US$716mn) in 2011 to SGD942mn (US$751mn) in 2012; +4.5% in local currency terms and +4.9% in US dollar terms. Forecast broadly in line with previous quarter.

Healthcare: SGD13.1bn (US$10.4bn) in 2011 to SGD14.5bn (US$11.5bn) in 2012; +10.9% in local currency terms and +11.2% in US dollar terms. Forecast broadly in line with previous quarter.

Medical devices: SGD449mn (US$357mn) in 2011 to SGD467mn (US$372mn) in 2012; +4.0% in local currency terms and +4.3% in US dollar terms. Forecast broadly unchanged from Q4 12.

Risk/Reward Ratings: Despite having higher risks scores and country rewards scores, Singapore will continue to rank fifth (out of the 18 key markets in Asia Pacific) behind China primarily due to its small and developed pharmaceutical market. Consequently in our Q113 Asia Pacific Pharmaceutical Risk/Reward Ratings, the country scores 61.9, behind China's 62.5.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    Singapore Pharmaceuticals And Healthcare Industry SWOT
    Singapore Political SWOT
    Singapore Economic SWOT
    Singapore Business Environment

PHARMACEUTICAL RISK/REWARD RATINGS

    Table: Asia Pacific Pharmaceutical Risk/Reward Ratings, Q113
    Rewards
    Risks

SINGAPORE – MARKET SUMMARY

REGULATORY REGIME

    Regional Harmonisation
    Intellectual Property Issues
    Trade Agreements
    Pricing And Reimbursement Regime
    Pricing And Reimbursement Developments

INDUSTRY TRENDS AND DEVELOPMENTS

    Epidemiology
    Non-Communicable Disease
    Communicable Disease
    Healthcare Sector
    Healthcare Provision
    Hospital Sector
    Electronic Medical Records
    Financing
    Healthcare Insurance
    Healthcare Company Developments
    Medical Tourism
    International Healthcare Collaboration
    Research & Development
    Bioscience Sector
    Research & Development Activities
    Clinical Trials
    Clinical Trials Industry Developments
    Medical Devices
    Table: Classification Of Medical Devices In Singapore
    Medical Devices Industry Developments

INDUSTRY FORECAST SCENARIO

    Overall Market Forecast
    Table: Pharmaceutical Sales Indicators 2008-2016
    Key Growth Factors – Industry
    Table: Healthcare Features In Budget 2011 And Budget 2012
    Table: Healthcare Expenditure Indicators 2008-2016
      Table: Healthcare Governmental Indicators 2008-2016
      Table: Healthcare Private Indicators 2008-2016
      Key Growth Factors – Macroeconomic
      Prescription Drug Market Forecast
      Table: Prescription Drug Sales Indicators 2008-2016
      Patented Drug Market Forecast
      Table: Patented Drug Market Indicators 2008-2016
      Generic Drug Market Forecast
      Table: Generic Drug Sales Indicators 2008-2016
      OTC Medicine Market Forecast
      Table: OTC Medicine Sales Indicators 2008-2016
      Pharmaceutical Trade Forecast
      Table: Exports and Imports Indicators 2008-2016
      Medical Device Market Forecast
      Table: Medical Devices Sales Indicators 2008-2016
      Other Healthcare Data Forecasts
      Key Risks To BMI’s Forecast Scenario

COMPETITIVE LANDSCAPE

      Pharmaceutical Industry
      Table: Pharmaceutical Manufacturing In Singapore
      Table: Singapore’s Leading Healthcare And Pharmaceutical Companies According To Market Capitalisation
      Domestic Pharmaceutical Sector
      Foreign Industry
      Foreign Company Activity
      Traditional Chinese Medicine
      Pharmaceutical Distribution
      Retail Pharmacies
      Developments in Pharmaceutical Supply Chain

COMPANY PROFILES

  Local Manufacturers
      Haw Par
      SciGen
      MerLion Pharmaceuticals
      Veredus Laboratories
  Multinational Companies
      Pfizer
      Novartis
      GlaxoSmithKline
      Sanofi
      Merck & Co
      Baxter

DEMOGRAPHIC OUTLOOK

      Table: Singapore’s Population By Age Group, 1990-2020 (‘000)
      Table: Singapore’s Population By Age Group, 1990-2020 (% of total)
      Table: Singapore’s Key Population Ratios, 1990-2020
      Table: Singapore’s Rural And Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

HOW WE GENERATE OUR PHARMACEUTICAL INDUSTRY FORECASTS

PHARMACEUTICAL RISK/REWARD RATINGS METHODOLOGY

RATINGS OVERVIEW

TABLE: PHARMACEUTICAL BUSINESS ENVIRONMENT INDICATORS

WEIGHTING

TABLE: WEIGHTING OF COMPONENTS

SOURCES
Skip to top


The Pharmaceutical Market: Vietnam US$ 1,295.00 Jan, 2013 · 110 pages
The Pharmaceutical Market: Egypt US$ 1,295.00 Jan, 2013 · 111 pages
The Pharmaceutical Market: Finland US$ 1,295.00 Mar, 2013
The Pharmaceutical Market: France US$ 1,295.00 Jan, 2013 · 107 pages

Ask Your Question

The Pharmaceutical Market: Singapore
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: